Table 3 Respondents’ concerns about sharing clinical trial data through a data repository, stratified by trialist and trial characteristics
From: Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey
| Â | Concerns about sharing clinical trial data through a data repository | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Respondents | No concern (%) | Any concern (%) | P value | Concerns related to investigator or funder interests (%) | P value | Concerns related to the protection of research subjects (%) | P value | Concerns related to appropriate data use (%) | P value | Other concerns (%) |
Overall | 317 | 77 (24) | 240 (76) | Â | 129 (41) | Â | 91 (29) | Â | 205 (65) | Â | 35 (11) |
Trialist academic productivity (number of research articles published in past three years) | Â | Â | Â | 0.32 | Â | 0.09 | Â | 0.59 | Â | 0.18 | Â |
     1 to 10 articles | 71 | 15 (21) | 56 (79) |  | 21 (30) |  | 22 (31) |  | 47 (66) |  | 7 (10) |
     11 to 25 articles | 117 | 25 (21) | 92 (79) | 52 (44) | 36 (31) | 82 (70) | 10 (9) | ||||
     >25 articles | 129 | 37 (29) | 92 (71) | 56 (43) | 33 (26) | 76 (59) | 18 (14) | ||||
Trialist geographic location | Â | Â | Â | 0.88 | Â | 0.93 | Â | 0.65 | Â | 0.70 | Â |
     United States or Canada | 167 | 41 (25) | 126 (75) |  | 68 (41) |  | 45 (27) |  | 111 (66) |  | 21 (13) |
     Western Europe | 113 | 26 (23) | 87 (77) | 45 (40) | 36 (32) | 72 (64) | 11 (10) | ||||
     Other | 37 | 10 (27) | 27 (73) | 16 (43) | 10 (27) | 22 (59) | 3 (8) | ||||
Trial funding source | Â | Â | Â | 0.18 | Â | 0.01 | Â | 0.34 | Â | 0.52 | Â |
     Government | 120 | 35 (29) | 85 (71) |  | 39 (33) |  | 32 (27) |  | 75 (63) |  | 16 (13) |
     Industry or mixed funding | 152 | 30 (20) | 122 (80) | 75 (49) | 42 (28) | 103 (68) | 13 (9) | ||||
     Other | 45 | 12 (27) | 33 (73) | 15 (33) | 17 (38) | 27 (60) | 6 (13) | ||||
Trial size | Â | Â | Â | 0.35 | Â | 0.10 | Â | 0.40 | Â | 0.84 | Â |
     ≤239 subjects | 80 | 24 (30) | 56 (70) |  | 26 (33) |  | 24 (30) |  | 52 (65) |  | 9 (11) |
     240 to 2,016 subjects | 158 | 34 (22) | 124 (78) | 64 (41) | 49 (31) | 104 (66) | 16 (10) | ||||
     ≥2,017 subjects | 79 | 19 (24) | 60 (76) | 39 (49) | 18 (23) | 49 (62) | 10 (13) | ||||
Journal in which the trial was published | Â | Â | Â | 0.29* | Â | 0.57 | Â | 0.81* | Â | 0.31 | Â |
     NEJM | 113 | 26 (23) | 87 (77) |  | 48 (42) |  | 30 (27) |  | 79 (70) |  | 13 (12) |
     Lancet | 70 | 11 (16) | 59 (84) | 31 (44) | 18 (26) | 48 (69) | 5 (7) | ||||
     JAMA | 43 | 14 (33) | 29 (67) | 16 (37) | 15 (35) | 26 (60) | 5 (12) | ||||
     Annals of Internal Medicine | 24 | 7 (29) | 17 (71) | 8 (33) | 8 (33) | 14 (58) | 4 (17) | ||||
     The BMJ | 53 | 16 (30) | 37 (70) | 18 (34) | 17 (32) | 32 (60) | 8 (15) | ||||
     PLoS Medicine | 14 | 3 (21) | 11 (79) |  | 8 (57) |  | 3 (21) |  | 6 (43) |  | 0 (0) |